Shares of Novo Nordisk plunged after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer’s disease failed to meet its main goal.
Recent Posts
- Shoppers curtail Black Friday plans to stretch spending: ‘They are using every tool that they can,’ expert says
- Michael Burry launches newsletter to lay out his AI bubble views after deregistering hedge fund
- Novo Nordisk shares plunge to four-year low after Alzheimer’s drug trial fails to hit key target
- Cash can feel safe, ‘but it doesn’t grow your wealth,’ portfolio strategist says
- Ukraine desperate to keep Trump on its side in peace talks, while saving its sovereignty